nach oben

CNS Drugs

Erschienen in:

01.11.2006 | Adis Spotlight

Spotlight on Eletriptan in Migraine

verfasst von: Paul L. McCormack, Gillian M. Keating

Erschienen in: CNS Drugs | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Eletriptan (Relpax®)² is an orally administered, lipophilic, highly selective serotonin 5-HT_1B/1D receptor agonist (‘triptan’) that is effective in the acute treatment of moderate to severe migraine attacks in adults. It has a rapid onset of action and demonstrates superiority over placebo as early as 30 minutes after the administration of a single 40 or 80mg oral dose. The efficacy of eletriptan 20mg was similar to that of sumatriptan 100mg, while eletriptan 40 and 80mg displayed greater efficacy than sumatriptan 50 or 100mg for most endpoints. Eletriptan 40mg was generally superior to naratriptan 2.5mg and equivalent to almotriptan 12.5mg, rizatriptan 10mg and zolmitriptan 2.5mg, while eletriptan 80mg was superior to zolmitriptan 2.5mg for most efficacy parameters. Eletriptan 40 and 80mg were consistently superior to ergotamine/caffeine. Eletriptan is generally well tolerated, reduces time lost from normal activities, improves patients’ health-related quality of life and appears to be at least as, if not more, cost effective than sumatriptan. Eletriptan is therefore a useful addition to the triptan family and a first-line treatment option in the acute management of migraine attacks.

Napier C, Stewart M, Melrose H, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [³H]eletriptan binding at human 5-HT_1B and 5-HT_1D receptors. Eur J Pharmacol 1999; 368: 259–68PubMedCrossRef

Bardsley-Elliot A, Noble S. Eletriptan. CNS Drugs 1999 Oct; 12(4): 325–33CrossRef

Willems E, De Vries P, Heiligers JPC, et al. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT_1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 212–9PubMedCrossRef

Gupta P, Butler P, Shepperson NB, et al. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT_1B/1D receptor agonist. Eur J Pharmacol 2000 Jun 9; 398(1): 73–81PubMedCrossRef

MaassenVanDenBrink A, van den Broek RW, de Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000 Nov 28; 55(10): 1524–30PubMedCrossRef

Gupta P, Brown D, Butler P, et al. Preclinical in vivo pharmacology of eletriptan (UK-116,044): a potent and selective partial agonist at the “5HT_1D-like” receptor [abstract no. 77]. Cephalalgia 1996; 16: 386

Knyihar-Csillik E, Tajti J, Csillik AE, et al. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000 Nov; 12(11): 3991–4002PubMedCrossRef

Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999; 82: 15–22PubMedCrossRef

Lambert GA, Boers PM, Hoskin KL, et al. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002 Oct 25; 953(1–2): 181–8PubMedCrossRef

10.

Johnson DE, Rollema H, Schmidt AW, et al. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol 2001 Aug 17; 425(3): 203–10PubMedCrossRef

11.

Evans DC, O’Connor D, Scott-Stevens P, et al. Central sites of action affect the antimigraine efficacy of 5-HT_1B/1D receptor agonists [abstract]. Headache Q 2001; 12(1): 45

12.

Evans DC, O’Connor D, Lake BG, et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003 Jul; 31(7): 861–9PubMedCrossRef

13.

Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT_1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002 May; 42(5): 528–39PubMedCrossRef

14.

Grujich NN, Gawel MJ. Eletriptan. Expert Opin Investig Drugs 2001 Oct; 10(10): 1869–74PubMedCrossRef

15.

Shah AK, Harris SC, Greenhalgh C, et al. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002 May; 42(5): 520–7PubMedCrossRef

16.

Pfizer Inc. Relpax® (eletriptan hydrobromide) tablets, US prescribing information [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Apr 27]

17.

Johnson BF, Shah A, Law G. The absorption kinetics of eletriptan in migraineurs [abstract]. Headache 1997 May; 37(5): 315

18.

Milton KA, Allen MJ, Abel S, et al. The safety, tolerability, and pharmacokinetics of oral and intravenous eletriptan, a potent and selective ‘5-HT_1D-like’ receptor partial agonist [abstract]. Headache 1997 May; 37(5): 324

19.

Morgan P, Rance DJ, James G, et al. An in vitro-in vivo correlation of eletriptan pharmacokinetics and metabolism in rat, dog, and human [abstract]. Headache 1997 May; 37(5): 324

20.

Milton KA, Allen MJ, Abel S. The safety, tolerability and pharmacokinetics of intravenous eletriptan (UK-116,044), a new potent and-selective ‘5HT_1D-like’ receptor agonist [abstract no. 76]. Cephalalgia 1996 Aug; 16(5): 385

21.

Hyland R, Jones BC, McCleverty P, et al. In vitro metabolism of eletriptan in human liver microsomes [abstract no. P.34]. Cephalalgia 1998; 18: 404

22.

Färkkilä M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23: 463–71PubMedCrossRef

23.

Fukuuchi Y, Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002 Jul; 22(6): 416–23CrossRef

24.

Stark R, Dahlof C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002 Feb; 22(1): 23–32PubMedCrossRef

25.

Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003 Mar; 43(3): 202–13PubMedCrossRef

26.

Färkkilä M, Eletriptan Steering Committee. A dose-finding study of eletriptan (UK-116,044) (5–30 mg) for the acute treatment of migraine [abstract no. 81]. Cephalalgia 1996; 16: 387–8

27.

Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000 Jan 11; 54(1): 156–63

28.

Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003 Mar; 43(3): 214–22PubMedCrossRef

29.

Sandrini G, Färkkilä M, Burgess G, et al. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002 Oct 22; 59(8): 1210–7PubMedCrossRef

30.

Diener HC, Ryan R, Sun W, et al. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol 2004 Feb; 11(2): 125–34PubMedCrossRef

31.

Lainez M, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006 Mar; 26(3): 246–56

32.

Vollono C, Capuano A, Mei D, et al. Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol 2005 Jul; 12(7): 557–63PubMedCrossRef

33.

Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003 Dec; 23(10): 942–52PubMedCrossRef

34.

Garcia-Ramos G, MacGregor EA, Hilliard B, et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003 Nov; 23(9): 869–76PubMedCrossRef

35.

Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47(2): 99–107PubMedCrossRef

36.

Funk Orsini PA, Miceli RJ. Improvement in migraine-specific quality of life with eletriptan (Relpax™) vs Cafergot® [abstract no. P2-K61]. Cephalalgia 2001 May; 21: 431–2

37.

Funk Orsini PA, Miceli RJ. Comparison of the impact of eletriptan (Relpax™) and sumatriptan on migraine-specific quality of life [abstract no. P2-K62]. Cephalalgia 2001 May; 21: 432

38.

Wells N, Hettiarachchi J, Drummond M, et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003 Jul; 6(4): 438–47PubMedCrossRef

39.

Gracia-Naya M, Rejas Gutiérrez J, Latorre Jiménez A, et al. Economic evaluation of acute migraine attack treatment with triptans in Spain [in Spanish]. Neurologia 2005 Apr; 20(3): 121–32PubMed

40.

Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005 Nov–Dec; 8(6): 647–55PubMedCrossRef

41.

Belsey JD. Cost effectiveness of oral triptan therapy: a transnational comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004 May; 20(5): 659–69PubMedCrossRef

42.

Wells NEJ, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000 Dec; 18(6): 557–66PubMedCrossRef

43.

Wells NEJ. The effectiveness of oral eletriptan (20–80 mg) at reducing the time loss associated with an acute migraine attack [abstract no. P05.138]. Neurology 2000 Apr 11; 54(7 Suppl. 3): 382

44.

Wells NEJ. Comparison of the effectiveness of eletriptan, sumatriptan and Cafergot® in reducing the time loss associated with migraine attacks. J Drug Assess 2001; 4: 265–74

45.

McKenzie I, Pitman V. Safety, tolerability, and efficacy of eletriptan (40 mg–80 mg) for long-term treatment of migraine [abstract no. P 3054]. Eur J Neurol 2000 Nov; 7Suppl. 3: 118

Titel: Spotlight on Eletriptan in Migraine
verfasst von: Paul L. McCormack
Gillian M. Keating
Publikationsdatum: 01.11.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620110-00008

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Varenicline

Cytomegalovirus and Schizophrenia

Neuraxial Drug Administration

Development of CRF1 Receptor Antagonists as Antidepressants and Anxiolytics

A Naturalistic Study of Galantamine for Alzheimer’s Disease